Romosozumab and Denosumab Combination Therapy After Denosumab in Postmenopausal Osteoporosis
Authors' conclusion
Ongoing treatment with Dmab did not blunt the anabolic response of Romo, indicating sustained modeling-based bone formation activity.
Study context
- Population
- Postmenopausal women with osteoporosis on long-term denosumab (Dmab)
- Participants
- 50 women
- Exposure
- Romosozumab (Romo) added to Dmab vs continued Dmab
- Dmab ➔ Dmab + Romon = 25
- Dmab ➔ Dmabn = 25reference
- Outcome
- Between-group difference (outcome not named in abstract)
- Follow-up
- M+12
Methodological detailspropensity-score matched, 36-month
- Propensity-score matched
- 36-month
Main finding
As reported in the abstract
Between-group difference at M+12: nonsignificant trend toward greater improvement with combination therapy
3.3%
95% CI −5.2 to 11.8
Observational data: associations, not effects.
Further findings
- P1nP change, Dmab ➔ Dmab + Romo · M0 to M+3 — Dmab ➔ Dmab + Romo
- +22.5 (SE 8.7) ng/mL
- P1nP change, Dmab ➔ Dmab + Romo — Significant increase
- P = 0.028
Original publication
Romosozumab and Denosumab Combination Therapy After Denosumab in Postmenopausal Osteoporosis. Arthritis Rheumatol. Published 22 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →